Keys to Accelerating Biologics Manufacturing

This is an exciting time for biologics. Investment in novel antibodies, biosimilars, and advanced modalities continues to expand, while outsourcing has become central to meeting global demand. Whether scaling up commercial supply or moving a molecule rapidly through clinical development, the ability to manufacture efficiently, safely, and at scale is now a competitive necessity.

Outsourcing to CDMOs provides access to facilities, expertise, and technologies that many companies cannot develop internally. But successful partnerships go beyond securing capacity. They depend on alignment across timelines, regulatory expectations, and technology platforms. Without a well-structured strategy, delays, cost overruns, and quality risks can undermine even the most promising biologic.

So, what are the main considerations when developing a robust outsourcing strategy for biologics? The first step is to identify critical success drivers for your program:

• Time to market – Define realistic but aggressive timelines for clinical and commercial supply.
• Compliance readiness – Ensure partners can meet EU, FDA, and global regulatory standards.
• Process scalability – Confirm that early-stage processes can transition smoothly into commercial volumes.
• Operational flexibility – Plan for demand variability, product diversification, and rapid tech transfer.

Once these drivers are clear, companies can take a risk-based approach to outsourcing — assessing CDMO capabilities, mapping potential bottlenecks, and building resilient supply chains.